← Browse by Condition
Medical Condition
recurrent mantle cell lymphoma
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 1
NCT05910801 Phase 2
Recruiting
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Enrollment
100 pts
Location
United States
Sponsor
Academic and Community Cancer ...
NCT07003295 Phase 2
Recruiting
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Enrollment
20 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT04484012 Phase 2
Recruiting
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Enrollment
36 pts
Location
United States
Sponsor
City of Hope Medical Center
NCT05432635 Phase 1
Recruiting
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Enrollment
15 pts
Location
United States
Sponsor
City of Hope Medical Center